Anne-Marie GRAFFIN

About Anne-Marie GRAFFIN

Anne-Marie Graffin is a highly experienced board director in the life sciences sector, with deep expertise in governance, strategy, and international business development. She currently holds a prominent leadership position as Chair of the Board of Directors of Valneva SE, a specialty vaccine company, following Valneva’s transition to a unitary board structure in December 2023. She also serves as Vice Chair of Nanobiotix’s Supervisory Board, where she has been involved since 2013, and is additionally a board member of Sartorius Stedim Biotech and Vetoquinol. At Nanobiotix, Graffin has played a long-standing governance role, first as a member of the Supervisory Board and later as its Vice Chair. She also chaired the Appointments and Remuneration Committee, reflecting her strong involvement in board composition, executive oversight, and compensation matters. This long tenure demonstrates an in-depth understanding of the challenges faced by listed biotechnology companies, including growth governance, capital structure discipline, innovation oversight, and the balance between scientific ambition and financial accountability. Her career also includes more than 20 years of experience in life sciences, including a notable position on the Executive Committee of Sanofi Pasteur MSD. That background gave her broad exposure to vaccine markets, healthcare strategy, product portfolio management, industrial partnerships, and international regulatory environments. As a result, she is widely positioned as a board leader with a strong long-term value perspective and a clear understanding of the governance expectations of public companies in the healthcare sector. At Valneva, her appointment as Chair of the Board signaled the company’s intent to rely on seasoned governance leadership to support strategic execution, investor confidence, and sustainable growth. With board experience across vaccines, biotech, and medtech, Anne-Marie Graffin is regarded as a rigorous and credible governance professional, well suited to overseeing innovative listed companies operating in highly regulated and international markets.